The Emerging Markets business continues Lilly’s legacy to deliver innovative medicines that address unmet needs and has a profound impact on people’s lives around the world.
More than 6,000 employees in 30 Lilly affiliates work across the 70 countries that make up Lilly’s Emerging Markets business.
What Makes Us Unique
With a well-balanced and diversified portfolio, the Emerging Markets business is driven with clear strategic choices in mind, and begins with establishing the “right footprint” of Lilly innovation, emphasizing strengths in diabetes, oncology and neuroscience. Diabetes is the highest priority therapeutic area across all geographies with the evolution of the disease. Over the past five years, 15 new molecular entities (NMEs) and new indication/line extensions (NILEX) have been launched in emerging markets. The Emerging Markets business area is experiencing a higher underlying growth as Lilly brings much needed medications to these countries. These factors combined will bring forth a significant share of global market growth.
China is the highest priority geography in Lilly emerging markets, followed by the ‘Five Focus’ Markets of Korea, Turkey, Russia, Brazil and Mexico. In addition, there are significant opportunities in other markets in Latin America, the Middle East, Africa and Asia where selective investment will occur.
We will build Lilly's business for tomorrow, today.
Lilly’s Emerging Markets business is building for tomorrow by serving the unique needs of its patients today. This can only be accomplished by understanding what our customers truly value and providing exceptional customer experiences, every day. Emerging Markets is committed to be a strong advocate for patients and to deliver the best possible healthcare outcomes.